Relay Therapeutics, Inc. Common Stock (RLAY) is a publicly traded Healthcare sector company. As of May 19, 2026, RLAY trades at $13.14 with a market cap of $2.34B and a P/E ratio of -7.54. RLAY moved +11.53% today. Year to date, RLAY is +47.92%; over the trailing twelve months it is +330.61%. Its 52-week range spans $1.78 to $17.32. Analyst consensus is strong buy with an average price target of $20.78. Rallies surfaces RLAY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own RLAY include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Relay Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $13.14 |
| Market Cap | $2.34B |
| P/E Ratio | -7.54 |
| EPS | $-1.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.32 |
| 52-Week Low | $1.78 |
| Volume | 9.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $10.68M |
| Net Income | $-272.70M |
| Gross Margin | 0.00% |
10 analysts cover RLAY: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.78.